OncoMed Pharmaceuticals, Inc.
OMED
OMED was delisted on the 22nd of April, 2019.
86 hedge funds and large institutions have $123M invested in OncoMed Pharmaceuticals, Inc. in 2016 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 31 increasing their positions, 25 reducing their positions, and 11 closing their positions.
129% more call options, than puts
Call options by funds: $1.06M | Put options by funds: $465K
24% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 25
3% less funds holding
Funds holding: 89 → 86 (-3)
27% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 11
32% less capital invested
Capital invested by funds: $181M → $123M (-$58.3M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Primecap Management
Pasadena,
California
|
+$4.58M |
| 2 |
Renaissance Technologies
New York
|
+$2M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$1.14M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$844K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$809K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$3.08M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$3.04M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.67M |
| 4 |
IHM
Iguana Healthcare Management
New York
|
-$1.61M |
| 5 |
ACA
Avoro Capital Advisors
New York
|
-$972K |
OMED Hedge Fund Activity: Q4 2016 in Review
86 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in OncoMed Pharmaceuticals, Inc. (OMED) for Q4 2016, worth a combined $123M — down 32% from $181M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of OMED and 8 opened new positions — a net loss of 3 holders — while 25 trimmed existing stakes and 31 added.
The largest buyer was Primecap Management, adding an estimated $4.58M. The largest seller was Millennium Management, cutting an estimated $3.08M.
- 86 institutional investors held OncoMed Pharmaceuticals, Inc. (OMED) as of Q4 2016, down from 89 in Q3 2016.
- Funds reported $123M of OncoMed Pharmaceuticals, Inc. stock for Q4 2016, down 32% quarter-over-quarter.
- 8 funds opened new OncoMed Pharmaceuticals, Inc. positions in Q4 2016 and 11 closed out, a net change of -3 holders.
- The largest OncoMed Pharmaceuticals, Inc. buyer in Q4 2016 was Primecap Management, an estimated $4.58M added.
- The largest OncoMed Pharmaceuticals, Inc. seller in Q4 2016 was Millennium Management, an estimated $3.08M sold.
Based on aggregated 13F filings for Q4 2016.